Početna › Akutna limfoblastna leukemija › Washington › Seattle
Kliničke studije za Akutna limfoblastna leukemija u gradu Seattle, WA
Jedna studija za Akutna limfoblastna leukemija traži sudionike na lokaciji u gradu Seattle ili blizu njega. Otvorite je da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
U tijeku regrutacija
- Seattle Children's, University of Washington, Seattle
- Fred Hutchinson Cancer Research Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- i još 1
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
U tijeku regrutacijaFaza 1
- Fred Hutchinson Cancer Center, Seattle
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
U tijeku regrutacijaFaza 2
- Seattle Children's Hospital, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
U tijeku regrutacijaFaza 1/2
- Seattle Children's Hospital, Seattle
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
U tijeku regrutacijaOpažajna studija
- Seattle Children's Hospital d/b/a Seattle Children's Research Institute, Seattle
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
U tijeku regrutacijaFaza 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
U tijeku regrutacijaFaza 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Multicenter HomeVENT: Home Values and Experiences Navigation Track
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
- Seattle Childrens Hospital, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
U tijeku regrutacijaOpažajna studija
- Fred Hutchinson Cancer Research Center, Seattle
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
U tijeku regrutacijaFaza 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
U tijeku regrutacijaFaza 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
U tijeku regrutacijaFaza 2Zdravi dobrovoljci dobrodošli
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
U tijeku regrutacijaFaza 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
U tijeku regrutacijaOpažajna studija
- Seattle Children's Hospital, Seattle
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
U tijeku regrutacijaFaza 3
- Ascentage Investigative Site #1806, Seattle
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
U tijeku regrutacijaFaza 2
- Fred Hutchinson Cancer Center, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
U tijeku regrutacijaFaza 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
U tijeku regrutacijaFaza 1
- Fred Hutchinson Cancer Research Center, Seattle
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
U tijeku regrutacijaFaza 1
- Fred Hutchinson Cancer Center, Seattle
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
U tijeku regrutacijaFaza 1
- Seattle Children's Hospital, Seattle
Studije za Akutna limfoblastna leukemija u drugim gradovima
- Houston, TX28 studija
- New York City, NY24 studija
- Baldwin Park, CA21 studija
- Chicago, IL19 studija
- Atlanta, GA19 studija
- Philadelphia, PA16 studija
- Memphis, TN16 studija
- Washington, DC16 studija
- Boston, MA15 studija
- Los Angeles, CA14 studija
- Durham, NC13 studija
- Mountain View, CA13 studija
Ostale studije u gradu Seattle
- Nemikrocelularni karcinom pluća53 studija
- Rak (sve vrste)49 studija
- Rak prostate42 studija
- Akutna mijeloična leukemija40 studija
- Rak dojke39 studija
- Metastatski karcinom39 studija
- Kolorektalni rak34 studija
- Rak pluća33 studija
- Rak jajnika30 studija
- Multipli mijelom22 studija
- Mijelodisplastični sindromi21 studija
- Rak mjehura21 studija
Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.